Navigation Links
Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
Date:4/24/2013

RICHMOND, Calif., April 24, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier , Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 12:50 pm ET on Wednesday, May 1, 2013, at the 12th Annual Needham Healthcare Conference which will be held in New York.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

 


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
2. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
3. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
4. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
5. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
7. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
8. Sangamo BioSciences Reports First Quarter 2012 Financial Results
9. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/21/2017)... BOULDER, Colo. , Jan. 20, 2017 ... ("Bioptix" or the "Company"), announced that on January 14, ... a plan under which the Company will terminate certain ... subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on ... completed within 30 days.  The Company may pay severance ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):